GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » PB Ratio

Vicore Pharma Holding AB (STU:6Y4) PB Ratio : 1.55 (As of Apr. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-01), Vicore Pharma Holding AB's share price is €0.651. Vicore Pharma Holding AB's Book Value per Share for the quarter that ended in Dec. 2024 was €0.42. Hence, Vicore Pharma Holding AB's PB Ratio of today is 1.55.

Good Sign:

Vicore Pharma Holding AB stock PB Ratio (=1.5) is close to 5-year low of 1.5.

The historical rank and industry rank for Vicore Pharma Holding AB's PB Ratio or its related term are showing as below:

STU:6Y4' s PB Ratio Range Over the Past 10 Years
Min: 0.77   Med: 2.93   Max: 7.45
Current: 1.5

During the past 12 years, Vicore Pharma Holding AB's highest PB Ratio was 7.45. The lowest was 0.77. And the median was 2.93.

STU:6Y4's PB Ratio is ranked better than
65.62% of 1274 companies
in the Biotechnology industry
Industry Median: 2.29 vs STU:6Y4: 1.50

During the past 12 months, Vicore Pharma Holding AB's average Book Value Per Share Growth Rate was 21.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -2.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -7.70% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 2.50% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Vicore Pharma Holding AB was 41.90% per year. The lowest was -18.00% per year. And the median was -2.50% per year.

Back to Basics: PB Ratio


Vicore Pharma Holding AB PB Ratio Historical Data

The historical data trend for Vicore Pharma Holding AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB PB Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.48 2.57 5.02 3.50 1.79

Vicore Pharma Holding AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.50 3.26 5.47 2.25 1.79

Competitive Comparison of Vicore Pharma Holding AB's PB Ratio

For the Biotechnology subindustry, Vicore Pharma Holding AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's PB Ratio falls into.


;
;

Vicore Pharma Holding AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Vicore Pharma Holding AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=0.651/0.419
=1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Vicore Pharma Holding AB  (STU:6Y4) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Vicore Pharma Holding AB PB Ratio Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines